View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
August 13, 2018updated 12 Jul 2022 1:13pm

Samsung Bioepis to begin Phase l trial of SB26 for pancreatitis

Samsung Bioepis is set to start a Phase l trial to investigate SB26, also known as TAK-671, for the treatment of severe acute pancreatitis.

Samsung Bioepis is set to start a Phase l trial to investigate SB26, also known as TAK-671, for the treatment of severe acute pancreatitis.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Pancreatitis is caused by the inflammation of the pancreas, a large organ behind the stomach that produces digestive enzymes and various hormones.

Samsung’s planned Phase l trial is a randomised, double-blind, placebo-controlled, single and multiple-dose escalation study that intends to evaluate the safety, tolerability and pharmacokinetics of intravenous SB26 in healthy subjects.

Results from the trial are expected to be available by the third quarter of 2020.

Samsung Bioepis senior vice-president and Clinical Sciences Division head Chul Kim said: “The upcoming clinical trial marks a major milestone for those of us at Samsung Bioepis, as SB26 is set to become the first novel biologic candidate from our company to enter clinical trials.

“Acute pancreatitis remains one of the most common gastrointestinal conditions, affecting more patients every year.”

“Acute pancreatitis remains one of the most common gastrointestinal conditions, affecting more patients every year.

“While mild acute pancreatitis is more easily treatable, severe acute pancreatitis, which affects approximately 20% of patients suffering from acute pancreatitis, can often be fatal. Unfortunately, treatment options remain extremely limited.”

SB26 is an ulinastatin-Fc (UTI-Fc) fusion protein developed to treat severe acute pancreatitis.

It has been developed under a risk-sharing strategic collaboration agreement between Samsung Bioepis and Takeda Pharmaceutical Company to jointly develop new biologic therapies.

SB26 combines Samsung Bioepis’ biologics development platform with Takeda’s expertise in drug development.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena